FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

| STATEMENT | OF | CHANGES | IN I | BENEFICIA | L O | WNERS | HIP |
|-----------|----|---------|------|-----------|-----|-------|-----|
|           |    |         |      |           |     |       |     |

| OMB APPROVAL             |           |  |  |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |  |  |
| hours per response:      |           |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  DENYES NANCY   |     |   |                |                | 2. Issuer Name and Ticker or Trading Symbol aTYR PHARMA INC [ LIFE ] |   |        |   |  |   |   |                                     |                       | Relationship<br>eck all appli<br>Directo                     | cable)<br>or  | g Pers                              | 10% O  | vner   |            |
|--|-----|---|----------------|----------------|--|---|--------|---|--|---|---|-------------------------------------|-----------------------|--|---|-------------------------------------|--|--|------------|
| (Last)<br>3545 JO  |     | 3. Date of Earliest Transaction (Month/Day/Year) 02/03/2023 |                |                |  |   |        |   |  |   |   | Officer (give title below)  General |                       | Other (spec<br>below)  |   |                                     |  |  |            |
| (Street) SAN DII   |     |   | 92121<br>(Zip) |                | 4. If  | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |        |   |  |   |   |                                     |                       | Line   | ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person |                                     |  |  |            |
|  |     | Tab   | le I - Non     | -Deriv         | ative  | Sec   | uriti  | ies Ac                                  | quired   | , Dis   | posed o   | of, or                              | Ben                   | eficial  | ly Owned  | t                                   |  |  |            |
| 1. Title of Security (Instr. 3)  2. Transa Date (Month/D   |     |   |                | eay/Year) if a |  | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |        | 3.<br>Transaction<br>Code (Instr.<br>8) |  | 4. Securities Acquired (A<br>Disposed Of (D) (Instr. 3,<br>5) |   | i (A) or<br>: 3, 4 and              | Securitie<br>Benefici | . Amount of<br>securities<br>seneficially<br>owned following |   | n: Direct<br>r Indirect<br>istr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)        |  |            |
|  |     |   |                |                |  |   |        |   | Code   | v   | Amount  | : (                                 | (A) or<br>(D)         | Price  | Transac<br>(Instr. 3  | tion(s)                             |  |  | (111511.4) |
| Common stock 02/03   |     |   |                | 02/03          | 3/2023   | /2023   |        | M <sup>(1)</sup>                        |  | 2,68  | 2,688 A   |                                     | (2)                   | 7,079(3)   |   |                                     | D  |  |            |
|  |     | Т   | able II - D    |                |  |   |        |   |  |   | osed of<br>converti   |                                     |                       |  | Owned   |                                     |  |  |            |
| 1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year) |     | 3A. Deemed<br>Execution D<br>if any<br>(Month/Day           | on Date, T     |                | 4.<br>Transaction<br>Code (Instr.<br>8)                              |   | ı of i |   | 6. Date Exercisable a<br>Expiration Date<br>(Month/Day/Year) |   | e and 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4) |                                     |                       | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)          | 9. Number<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4)                    | s<br>S<br>Ily                       | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |            |
|  |     |   |                | ,              | Code   | v   | (A)    | (D)                                     | Date<br>Exercisa   |   | Expiration<br>Date  | Title                               | 1                     | Amount<br>or<br>Number<br>of<br>Shares                       |   |                                     |  |  |            |
| Restricted   | (2) | 02/03/2023  |                |                | м  |   |        | 2 688                                   | (4)  | - 1   | (4)   | Comr                                | non                   | 2 688  | \$0.00  | 8.062                               | ,  | D  |            |

## **Explanation of Responses:**

- 1. Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
- 2. Restricted stock units convert into common stock on a one-for-one basis.
- 3. Includes 944 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 15, 2022.
- 4. The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

## Remarks:

/s/ Nancy E. Denyes

02/06/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.